CRP and rheumatoid arthritis: In RA patients, TNF-α is an important mediator of IR; therefore, biological therapies that block proinflammatory cytokines, such as TNF-α antagonists, can reduce CRP levels in RA patients, as well as modulate lipid metabolism and improve IR (116).